Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $9.80 Average Price Target from Brokerages

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has been assigned an average rating of “Buy” from the six research firms that are currently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $9.80.

A number of research firms recently commented on AQST. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research note on Wednesday, November 6th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. Finally, Leerink Partners raised their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth $27,000. nVerses Capital LLC bought a new position in Aquestive Therapeutics during the 3rd quarter worth about $28,000. SG Americas Securities LLC purchased a new position in Aquestive Therapeutics during the 1st quarter valued at about $54,000. The Manufacturers Life Insurance Company bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at about $76,000. Finally, Financial Advocates Investment Management lifted its position in shares of Aquestive Therapeutics by 70.0% in the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after purchasing an additional 14,000 shares during the period. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Aquestive Therapeutics Price Performance

NASDAQ:AQST opened at $5.09 on Tuesday. The company has a market cap of $464.10 million, a price-to-earnings ratio of -11.31 and a beta of 2.82. Aquestive Therapeutics has a 1 year low of $1.84 and a 1 year high of $6.23. The stock’s 50 day simple moving average is $4.99 and its two-hundred day simple moving average is $3.99.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the firm earned ($0.03) earnings per share. As a group, analysts anticipate that Aquestive Therapeutics will post -0.47 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.